New Advances in Relapsed/Refractory Multiple Myeloma: Current Guidance and Future Perspectives

Join expert faculty on these live, interactive Webinars as they discuss the latest current and investigational treatment strategies for the management of patients with relapsed and refractory multiple myeloma.

Thank you for your interest in attending the Clinical Care Options (CCO) symposium, “New Advances in Relapsed/Refractory Multiple Myeloma: Current Guidance and Future Perspectives” that was originally scheduled as an in-person symposium in Chicago, Illinois. Due to the global impact of COVID-19, ASCO organizers have decided to host the ASCO Annual Meeting in a virtual format.

As such, this live symposium will also now be held as a virtual live Webinar. Please note that each Webinar will still feature the original expert faculty, interactivity, evidence-based content, and panel discussions as the in-person symposium. When participating in a live Webinar, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you,
CCO Member Services


  • Program Introduction
  • Overview of Relapsed/Refractory Multiple Myeloma
  • Therapeutic Strategies for Patients With Heavily Pretreated Myeloma After Relapse
  • Promising New Treatment Options for Patients With R/R Myeloma
  • Spotlight on Clinical Trials in R/R Myeloma
  • Closing Remarks and Question and Answer Session


Date / Time
Event Details


Natalie S. Callander, MD

Professor of Medicine
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Shaji Kumar, MD

Department of Hematology
Mayo Clinic
Rochester, Minnesota

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate new and emerging therapies into the treatment of patients with relapsed/refractory multiple myeloma.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the efficacy and safety evidence of novel combination therapeutic regimens for R/R MM
  • Explain the mechanism of action of newer classes of agents indicated for and under investigation for R/R MM
  • Select optimal therapies for patients with heavily pretreated R/R MM based on individual patient and disease characteristics
  • Manage toxicities with newer agents and combination regimens in patients with heavily pretreated R/R MM
  • Identify patients with R/R MM who would be eligible for enrollment in late-phase clinical trials


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity or enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.